Lumoxiti Disease Interactions

Hemolytic Uremic Syndrome (HUS), including life threatening cases, has been reported in patients treated with moxetumomab pasudotox, and is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and progressive renal failure. Avoid moxetumomab pasudotox in patients with prior history of severe thrombotic microangiopathy (TMA) or HUS. Monitor blood chemistry and complete blood counts prior to each dose and on Day 8 of each treatment cycle. Monitoring mid- cycle is also recommended. Consider the diagnosis of HUS in patients who develop hemolytic anemia, worsening or sudden onset of thrombocytopenia, increase in creatinine levels, elevation of bilirubin and/or LDH, and have evidence of hemolysis based on peripheral blood smear schistocytes. The events of HUS may be life-threatening if treatment is delayed with increased risk of progressive renal failure requiring dialysis. If HUS is suspected initiate appropriate supportive measures, including fluid repletion, hemodynamic monitoring, and consider hospitalization as clinically indicated. Discontinue treatment with moxetumomab pasudotox in patients with HUS.

Renal toxicity has been reported in patients treated with moxetumomab pasudotox . Patients have reported renal toxicity, including acute kidney injury, renal failure, serum creatinine increase, and proteinuria. Patients with renal impairment are at increased risk for worsening of renal function during or following treatment. Caution and monitoring is advised if using in patients with renal impairment. The use of moxetumomab pasudotox is not recommended in patients with severe renal impairment (CrCl = 29 mL/min).